ArticleEClinicalMedicine2023
Population attributable fraction of hypertension for dementia: global, regional, and national estimates for 186 countries.
Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.The lancet. Healthy longevity · 2024Pooled it
- High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT.Hypertension (Dallas, Tex. : 1979) · 2024Trial
- Incorporating Individual-Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations.Journal of the American Heart Association · 2024Trial
- Multi-ancestry multi-trait analysis reveals shared genetics across major psychiatric disorders and Alzheimer's disease.Translational psychiatry · 2026Article
- Article
- Addressing cognitive impairment in drivers on hemodialysis through reaction time.Dementia & neuropsychologia · 2026Article
- Neuroendocrine-vascular interaction is associated with thalamocortical disorganization and cognitive decline in perimenopausal hypertension.Frontiers in medicine · 2026Article
- Polygonati Rhizoma Alleviates Vascular Dementia through Regulating Microglial Polarization Transitions Mediated by NF-κB/NLRP3 Pathway.Current pharmaceutical biotechnology · 2026Article
- Activity Engagement Across Stages of Cognitive Health.Healthcare (Basel, Switzerland) · 2025Article
- Associations of digestive diseases exposure and lifestyle factors with Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Associations between serum lipid levels and cognitive impairment in hypertensive patients: a case-control study.BMC neurology · 2025Article
- Altered protein homeostasis in cardiovascular diseases contributes to Alzheimer's-like neuropathology.Basic research in cardiology · 2025Article
- Blood pressure and the brain: the conundrum of hypertension and dementia.Cardiovascular research · 2025Review
- Blood Pressure and Cognitive Function in Older Adults.Clinics in geriatric medicine · 2024Review
- Synergistic associations of CD33 variants and hypertension with brain and cognitive aging among dementia-free older adults: A population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Prevalence of childhood hypertension and associated factors in Zhejiang Province: a cross-sectional analysis based on random forest model and logistic regression.BMC public health · 2024Article
- Longitudinal Patterns of Systolic Blood Pressure, Diastolic Blood Pressure, Cardiorespiratory Fitness, and Their Association With Dementia Risk: The HUNT Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- The Rationale for Using Fixed-Dose Combination Therapy in the Management of Hypertension in Colombia: A Narrative Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Review
- A detection model of cognitive impairment via the integrated gait and eye movement analysis from a large Chinese community cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Current perspectives on prevention of vascular cognitive impairment and promotion of vascular brain health.Expert review of neurotherapeuticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Background: Quantifying the proportion of dementia attributable to highly prevalent modifiable risk factors, such as hypertension, is important in informing effective dementia prevention strategies. We aim to quantify the population attributable fraction (PAF) of hypertension for dementia (the proportion of dementia cases that would not occur if hypertension was eliminated) at global, regional, and national levels. Methods: In this study, we searched international and governmental websites for global, regional, and national data reporting population hypertension (according to 10-year age categories) and dementia prevalence. MEDLINE was searched for studies reporting the risk of dementia from age at hypertension diagnosis from database inception to December 31, 2022. Longitudinal observational studies with >500 participants reporting hazard ratios by age at hypertension diagnosis for risk of future all-cause dementia were eligible for inclusion. Studies excluded had cross-sectional methodology, specific vascular dementia or 'cognitive impairment' outcomes, and no age-specific metrics of association reported. The PAF of hypertension for dementia was calculated globally and for each country and region worldwide. Findings: Data from the Global Burden of Disease, United Nations Population Prospectus, NCD Risk Factor Collaboration, UK Biobank, and Atherosclerosis Risk in Communities Study were obtained. 186 countries reported dementia and hypertension prevalence data. The global PAF of hypertension for dementia was 15.8% [95% Credible Interval (CI), 8.8%-22.7%]. Latin America and the Caribbean (18.0% [95% CI, 9.4%-26.6%]), and Europe (17.2% [95% CI, 9.6%-24.7%]) had the highest PAF of hypertension for dementia. Hypertension diagnosed between the ages of 30-44 had the highest age-specific global attributable fraction for dementia (8.4% [95% CI, 3.4%-13.5%]), followed by ages 45-54 (2.92% [ 95% CI, 0.96%-4.88%]), 55-64 (2.59% [95% CI, 1.15%-4.03%]) and 65-74 (1.82% [95% CI, -2.31%-5.96%]). Interpretation: The population attributable risk of hypertension for dementia is 15.8%, suggesting that optimal detection and treatment, particularly at midlife, has the potential to markedly reduce the global burden of dementia. Funding: Wellcome Trust; Health Research Board of Ireland; Alzheimer's Association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.